By Fineline Cube ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced that the first patient has been dosed in the Phase 2 trial (IMM2510-HCC-201) of IMM2510 (palverafusp alfa) in combination with IMM27M (tazlestobart) for the first-line treatment of patients with advanced hepatocellular carcinoma (HCC). The milestone advances ImmuneOnco’s ambition to challenge established regimens in one of the deadliest and most treatment-resistant solid tumors.
Clinical Milestone
| Element | Detail |
|---|---|
| Company | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) |
| Trial | Phase 2 IMM2510-HCC-201 |
| Regimen | IMM2510 (palverafusp alfa) + IMM27M (tazlestobart) |
| Indication | First-line treatment of advanced hepatocellular carcinoma (HCC) |
| Milestone | First patient dosed |
| Date | 28 Aug 2026 |
| Next Steps | Evaluation of preliminary efficacy and safety of the combination in first-line HCC |
Drug Profile & Mechanism of Action
- IMM2510 (palverafusp alfa): Bispecific molecule targeting VEGF and PD-L1 with a proprietary mAb-Trap structure, combining anti-angiogenic and immune-activating functions in a single agent
- IMM27M (tazlestobart): Next-generation CTLA-4 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity
- Combination Rationale: Simultaneously blocks the PD-L1, VEGF, and CTLA-4 pathways for more comprehensive tumor microenvironment modulation
- Therapeutic Target: Addresses the two key challenges in HCC — immunosuppression and abnormal angiogenesis
Clinical Evidence – Phase 1b Foundation
| Study | Population | Key Readout |
|---|---|---|
| Phase 1b trial (advanced solid tumors) | Multiple tumor types | Recommended Phase 2 dose (RP2D) determined |
| Esophageal squamous cell carcinoma cohort | ESCC patients on the combination | 50% objective response rate (ORR) |
| Tolerability | Across the Phase 1b study | Generally good tolerability profile |
The combination enters the HCC Phase 2 with encouraging early signal: the RP2D was established in a Phase 1b trial for advanced solid tumors, where the regimen demonstrated a 50% ORR with generally good tolerability in patients with esophageal squamous cell carcinoma. The newly initiated study will now evaluate the preliminary efficacy and safety of this regimen as a first-line treatment for advanced HCC.
Market Impact & Outlook
- High-Stakes Setting: First-line advanced HCC remains one of oncology’s most competitive battlegrounds, currently dominated by PD-L1 plus anti-VEGF combinations — ImmuneOnco’s triple-pathway approach aims to differentiate within that standard of care
- Mechanistic Differentiation: Adding an enhanced-ADCC CTLA-4 antibody to a VEGF/PD-L1 bispecific targets immunosuppression and angiogenesis simultaneously, a broader mechanism than current approved regimens
- Early Clinical Momentum: The 50% ORR observed in esophageal squamous cell carcinoma provides a proof-of-concept signal that supports expansion into HCC
- Portfolio Strategy: The milestone reinforces ImmuneOnco’s (HKG: 1541) pipeline depth across its mAb-Trap bispecific platform and broadens potential commercial indications beyond its existing programs
Forward‑Looking Statements – This brief contains forward-looking statements regarding clinical outcomes, trial progression, and market potential. Early-phase efficacy results are not indicative of later outcomes. Actual results may differ materially. Not investment advice.-Fineline Info & Tech